Clinical pharmacology of intravitreal anti-VEGF drugs
Top Cited Papers
- 5 February 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Eye
- Vol. 32 (6), 1010-1020
- https://doi.org/10.1038/s41433-018-0021-7
Abstract
Clinical efficacy of intravitreal anti-VEGF drugs has been widely demonstrated in several angiogenesis-driven eye diseases including diabetic macular edema and the neovascular form of age-related macular degeneration. Pegaptanib, ranibizumab, and aflibercept have been approved for use in the eye, whereas bevacizumab is widely used by ophthalmologists to treat patients “off-label”. These drugs are active in the nanomolar to picomolar range; however, caution is required when establishing the rank order of affinity and potency due to in vitro inter-experimental variation. Despite the small doses used for eye diseases and the intravitreal route of administration may limit systemic side effects, these drugs can penetrate into blood circulation and alter systemic VEGF with unknown clinical consequences, particularly in vulnerable groups of patients. Clinical pharmacokinetics of ocular anti-VEGF agents should therefore be taken into account when choosing the right drug for the individual patient. The gaps in current understanding that leave open important questions are as follows: (i) uncertainty about which drug should be given first, (ii) how long these drugs can be used safely, and (iii) the choice of the best pharmacological strategy after first-line treatment failure. The current review article, based on the information published in peer-reviewed published papers relevant to anti-VEGF treatments and available on the PubMed database, describes in detail the clinical pharmacology of this class of drugs to provide a sound pharmacological basis for their proper use in ophthalmology clinical practice.Keywords
This publication has 102 references indexed in Scilit:
- Targeted deletion of Vegfa in adult mice induces vision lossJCI Insight, 2012
- Antiangiogenic Therapy for Ischemic RetinopathiesCold Spring Harbor Perspectives in Medicine, 2012
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis, 2012
- PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE)Retina, 2011
- Anti-VEGF Agents for Ocular Angiogenesis and Vascular PermeabilityJournal of Ophthalmology, 2011
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)Diabetes Care, 2010
- An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillarisProceedings of the National Academy of Sciences of the United States of America, 2009
- Renal FcRn Reclaims Albumin but Facilitates Elimination of IgGJournal of the American Society of Nephrology, 2009
- TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATIONRetina, 2009
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006